CHUGAI mit News - 500 Beiträge pro Seite

[Ikarus]

Wednesday, April 19, 2000
Chugai Pharm Develops Automated Blood
Testing Machine

TOKYO (Nikkei)--A U.S. subsidiary of Chugai Pharmaceutical Co. (4519)
has developed a fully automated machine to test blood for the presence
of HIV, Hepatitis C and other viruses, company sources said
Wednesday.

The equipment is expected to be marketed to blood centers in Japan and
the U.S. as early as 2001.

The Tokyo-based drug company expects the machine to improve testing
efficiency and accuracy, which is critical since viruses present in donated
blood pose a serious health risk.

Developed by Gen-Probe Inc., which specializes in diagnostic agents, the
equipment detects viruses in only three and a half hours by multiplying a
specific part of a virus gene sequence.

Unlike conventional testing methods, the new machine can detect viruses
before the antibodies needed to fight them are created, enabling faster
medical treatment.

Chugai hopes the equipment will reduce the cost per test to 1,000-1,500
yen from 10,000 yen.

Each year, about 15 million blood samples are tested around the world for
the presence of viruses.

(The Nihon Keizai Shimbun Thursday morning edition)

Saturday, April 22, 2000
Chugai Pharm To Use Humanized Antibody In
Cancer Treatments

TOKYO (Nikkei)--In developing cancer treatments, Chugai
Pharmaceutical Co. (4519) will use a humanized antibody which targets
designated cells, The Nihon Keizai Shimbun learned Saturday.

The drugmaker aims to begin clinical trials of two agents to treat bone
cancer later this year. It will likely take six to seven years to bring them to
market, sources at the company said.

Domestic and overseas firms are vying to develop drugs exploiting
human antibodies, which do not harm healthy cells and are therefore said
to cause fewer side effects.

Chugai is also working on a project to develop humanized
antibody-based treatments for rheumatism.

(The Nihon Keizai Shimbun Sunday edition)

[bart11]

hallo und danke fuer die news. was seht ihr fuer chugai als realistisches kz? verfolge die aktie seit einiger zeit und bin auch investiert. meiner meinung nach koennte bis jahresende ein kz von 40 - 45 euro realistisch sein. kommentare?

[Dos Players]

Hi, CHUGAILER

Habe im März 1000 Anteile zu 16,50 € erworben das sind bis heute gut und gerne 35% Plus.
Ein Kursziel bis Weihnachten 2000 von ca. 50€ ist durchaus drin.
Um Wiederholungen zu vermeiden schaut euch die bisherigen gesendeten Meinungen und Fakten an.
Werde noch einige Anteile kaufen.

Alles was uns wirklich nützt,
ist für wenig Geld zu haben.
Nur das Überflüssige kostet viel.
( Axel Munthe )

[Ikarus]

Molecular Biosystems, Mallinckrodt
Announce Restructuring of OPTISON(R)
Agreement

PR Newswire - May 08, 2000 16:58

Jump to first matched term

ST. LOUIS, and SAN DIEGO, May 8 /PRNewswire/ -- Molecular
Biosystems, Inc. (OTC Bulletin Board: MBIO) and Mallinckrodt Inc.
(NYSE: MKG) announced today the restructuring of their agreement
concerning OPTISON(R), the only U.S. Food and Drug
Administration-approved intravenous ultrasound contrast agent. Under
the terms of the agreement, Mallinckrodt will assume full control of the
OPTISON business, including responsibility for intellectual property
disputes, clinical development, manufacturing and real estate.

The announcement about the restructured agreement between
Molecular Biosystems and Mallinckrodt follows an earlier news release
on Monday that a settlement had been reached in three ongoing patent
disputes in Washington, D.C., Seattle, Wash., and Europe between
Nycomed Amersham plc (London: NAM; NYSE: NYE), Mallinckrodt,
Molecular Biosystems (MBI) and SONUS Pharmaceuticals Inc. In
addition, Nycomed and Mallinckrodt announced the formation of an
alliance in the ultrasound business for the development and marketing
of ultrasound contrast agents, starting with OPTISON.

As a result of Molecular Biosystems and Mallinckrodt`s restructured
agreement, MBI will receive an ongoing royalty of 5 percent on sales of
ultrasound contrast agents by Mallinckrodt and Nycomed in the
Mallinckrodt territory, which is worldwide, excluding Japan, South
Korea and Taiwan. In addition, MBI will pay a total of $7 million to
Mallinckrodt as part of the intellectual property settlement, $3 million
of which will be paid initially.

Chugai Pharmaceuticals, one of the six largest pharmaceutical
companies in Japan, is MBI`s partner for Japan, South Korea and
Taiwan. Japan is estimated to be the second largest market for
contrast agents in the world. Chugai recently initiated Phase III
studies for both the myocardial perfusion indication and for liver
imaging, the latter regarded by independent experts as the primary
opportunity in Japan. MBI receives a 28 percent royalty plus certain
milestone payments from Chugai and has no manufacturing or clinical
development responsibilities.

Molecular Biosystems` Chief Executive Officer Bobba Venkatadri,
commented, "It was necessary to restructure our agreement with
Mallinckrodt at this time to limit our current expenses and ensure the
potential for future shareholder value. It was a very difficult decision.
However, because of the slow ramp-up of OPTISON sales in the U.S.
and Europe and escalating legal expenses to Molecular Biosystems (in
excess of 40% of MBI`s current expenses), management and the Board
of Directors determined that it was in the best interest of the
shareholders to take this action. We are pleased that OPTISON will be
co-promoted by two world leaders in the contrast media business and
look forward to the financial benefit of this new alliance. With the new
agreement, MBI can focus its efforts going forward on assisting
Chugai with its development of FS069 and can also pursue several
strategic alternatives with regard to corporate development which now
become available to us."

Mallinckrodt Imaging Group President Bradley J. Fercho said,
"Mallinckrodt`s restructured agreement with Molecular Biosystems,
coupled with our agreement with Nycomed Amersham, provide
exciting opportunities for enhancing the development of additional
cardiology and radiology indications beyond those existing today in the
ultrasound field. We have made major investments to develop the
ultrasound field and to enhance the utility of ultrasound as a diagnostic
tool and are excited about the potential for the future. The plans for
making the transition in our working relationship with Molecular
Biosystems will be completed in the near future."

MBI, based in San Diego, California, is a world leader in developing
contrast agents for diagnostic imaging. Its innovative product,
OPTISON, enables improved diagnosis of heart disease through clearer
ultrasound images.

Mallinckrodt Inc. is a global manufacturer and marketer of specialty
medical products designed to sustain breathing, diagnose disease and
relieve pain. Named one of America`s most admired medical products
and equipment companies by Fortune magazine, Mallinckrodt does
business in more than 100 countries. In fiscal 1999, combined net
sales were $2.6 billion for Mallinckrodt`s respiratory, imaging and
pharmaceutical product lines. Based in St. Louis, Missouri,
Mallinckrodt`s website address is ( www.mallinckrodt.com ).

This news release contains forward-looking statements that involve
risks and uncertainties. These statements are based on current
expectations; actual results may differ materially. Among the factors
that could cause actual results to differ materially from those projected
are the following: the effect of business and economic conditions; the
impact of competitive products and continued pressure on prices
realized by the company for its products; constraints on supplies of
raw materials used in manufacturing certain of the company`s
products; capacity constraints limiting the production of certain
products; difficulties or delays in the development, production, testing,
and marketing of products; difficulties or delays in receiving required
governmental or regulatory approvals; market acceptance issues,
including the failure of products to generate anticipated sales levels;
difficulties in rationalizing acquired businesses and in realizing related
cost savings and other benefits; the effects of and changes in trade,
monetary and fiscal policies, laws and regulations; foreign exchange
rates and fluctuations in those rates; the costs and effects of legal and
administrative proceedings, including environmental proceedings and
patent disputes involving the company; difficulties or delays in
addressing "Year 2000" problems in the company`s operations, or the
inability of a major supplier or customer to continue operations due to
such problems; and the risk factors reported from time to time in the
company`s SEC reports. The company undertakes no obligation to
update any forward-looking statements as a result of future events or
developments.

[Mr.r]

Hallo !
Hat jemand eine Internetadresse bei der man die Kurse aus Tokio abfragen kann? Das währe echt nett!

[Dos Players]

http://www.asiainternet.de/
WKN der Aktie eingeben und schon gehts los.

[Mr.r]

Danke!

[zea]

Hallo Boardmitglieder - gibt es irgendwelche Neuigkeiten von CHUGAI oder ist der Kursverfall in den letzten Tagen dem Markt entsprechend zu erklären?

Möchte nämlich früh genug mit satten Gewinnen aussteigen... ;-)

[Dos Players]

BERICHTE
Finanzmärkte und Kapitalanlage
Wirtschaft und
Unternehmen

Sat, 20 May 2000, 3:06pm MEZ

Japans Broker locken Privatanleger mit kostenlosen Nachrichten

Tokio, 18. Mai (Bloomberg) - In Japan tobt unter Banken und
Brokern der Kampf um die Privatanleger. Japans Broker locken
Privatanleger jetzt, indem sie ihnen die gleichen Investment-
Informationen und Nachrichten anbieten wie sie institutionelle
Anleger erhalten - und zwar gratis.

So stellt Nomura Securities Co., Japans grösstes Brokerhaus
und die Nummer 1 im Online-Trading, seinen Privatkunden seit
Anfang März Informationen über Aktienkurse und Handelsvolumina
kostenlos zur Verfügung. Unterstützt wird Nomura dabei von einer
Nachrichtenagentur von Nihon Keizai Shimbun, Japans grösster
Tageszeitung. Nach eigenen Angaben konnte der Broker seine Online-
Depots dadurch im vergangenen Monat um 43.000 auf 231.000 erhöhen.
,Im Moment haben alle Privatkunden die gleichen Informationen
wie institutionelle Anleger", sagt Takeo Omura, stellvertretender
Geschäftsführer des Daiwa Institute of Research Ltd. ,Aber das
wird sich voraussichtlich ändern, so dass nur noch die Kunden
kostenlos exklusive Informationen bekommen, die für die
Brokerhäuser auch wirklich rentabel sind."

Da das Privatkundengeschäft oftmals profitabler als das
Firmenkundengeschäft ist, bemühen sich Japans Banken und Broker
redlich um ihre Kunden. So hat DLJdirect-SFG Securities Inc.,
Japans sechstgrösster Online-Broker, seinen kostenlosen
Nachrichtendienst, den es mit Reuters Group Plc. betreibt, bis
September verlängert. Wie es danach weitergehen soll, hängt auch
von der Konkurrenz ab.

Der Konkurrenzdruck wächst kräftig, seit Japans Privatkunden
ihre fälligen Spareinlagen auf Postsparbüchern auflösen können und
unter den Banken ein wahrer Kampf um Privatanleger entfacht ist.
Ende März verzeichneten die Kreditinstitute zum ersten Mal seit
1990 Kapitalabflüsse. Rund 106 Billionen Yen, umgerechnet rund 975
Milliarden Dollar, werden innerhalb der nächsten zwei Jahre aus
Postsparbüchern fällig.
Über 50 japanische Broker bieten Online-Trading an, darunter
grosse Häuser wie Nomura und Daiwa Securities Co. Aber auch Joint-
Ventures zwischen japanischen Finanzgruppen und US-Brokern wie
E*Trade Group und Start-ups, hinter denen branchenfremde
Unternehmen wie Sony Corp. stehen, engagieren sich online.

Japans Privatkunden haben im März rund 775.000 Online-Konten
eröffnet, so das Ergebnis eine Bloomberg News-Studie, bei der 41
von 48 Online-Brokern befragt wurden. Mit 187.780 Konten stand
Nomura dabei an der Spitze, gefolgt von Daiwa mit 155.000 Online-
Kunden.

Kazu Hirano, Aiko Kikkawa und Tomomi Sekioka in Tokio / CB
(Japan Brokers Offer Free News to Retail Investors)
-0- (DBN) May/18/2000 11:33 GMT